Related Experiment Video

Updated: Jul 8, 2026

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

Coagulation and fibrinolytic protein kinetics in cardiopulmonary bypass

Maryam Yavari1, Richard C Becker

  • 1Duke Cardiovascular Thrombosis Center, Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27705, USA.

Journal of Thrombosis and Thrombolysis
|January 25, 2008
PubMed

Insights

Cardiopulmonary Bypass (CPB) revolutionized heart surgery but causes bleeding and clotting issues. Further research is needed to address these significant hemostatic challenges for patients.

Area of Science:

  • Cardiovascular Surgery
  • Hemostasis
  • Biomedical Engineering

Background:

  • Cardiopulmonary Bypass (CPB) is a cornerstone of modern cardiothoracic surgery.
  • CPB has dramatically improved outcomes for patients with congenital and acquired heart disease.
  • However, CPB is associated with significant hemostatic challenges.

Purpose of the Study:

  • To review the limitations of CPB.
  • To discuss the hemostatic perturbations associated with CPB.
  • To highlight the risks of bleeding and thrombosis in patients undergoing CPB.

Main Methods:

  • Literature review of studies on CPB and hemostasis.
  • Analysis of clinical data on bleeding and thrombotic complications.
  • Synthesis of current understanding of CPB-induced hemostatic changes.

Main Results:

  • CPB significantly alters coagulation and platelet function.
  • Increased risk of both bleeding and thrombotic events is observed in CPB patients.
  • Hemostatic challenges remain a critical concern in CPB management.

Conclusions:

  • Despite its benefits, CPB presents substantial hemostatic challenges.
  • Managing bleeding and thrombosis is crucial for patient safety during and after CPB.
  • Further investigation into mitigating CPB-related hemostatic complications is warranted.

More Related Videos

A Recovery Cardiopulmonary Bypass Model Without Transfusion or Inotropic Agents in Rats09:54

A Recovery Cardiopulmonary Bypass Model Without Transfusion or Inotropic Agents in Rats

Published on: March 23, 2018

Artificial Lung Device Priming for In Situ Fiber Bundle Surface Grafting08:53

Artificial Lung Device Priming for In Situ Fiber Bundle Surface Grafting

Published on: March 28, 2025

Related Concept Videos

Coagulation01:09

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Introduction to Hemostasis01:05

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...